HR Execs on the Move

NeoPharm

www.neopharm.com

 
NeoPharm, Inc. is a Waukegan, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.neopharm.com
  • 1850 S Lakeside Dr
    Waukegan, IL USA 60085
  • Phone: 847.887.0800

Executives

Name Title Contact Details

Similar Companies

International Drug Development Institute

International Drug Development Institute is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BELPORT COMPANY INC

BELPORT COMPANY INC is a Camarillo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Simcha Therapeutics

Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.

Medicinova

MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

Cygnal Therapeutics

Founded in 2017 by Flagship Pioneering, Cygnal Therapeutics is the first company to build a platform to develop drugs in the field of exoneural biology. Exoneural biology is broadly implicated in human health and disease. Fueled by our dynamic Exoneural Medicine Platform™, we are creating new medicines across multiple therapeutic areas, starting with cancer and inflammatory diseases.